In the News

Recent Coverage of HMS in the News
March 20, 2015

New research can help change your approach to managing your migraines. John Mafi, research fellow in medicine at Beth Israel Deaconess Medical Center, is quoted.   

March 20, 2015

Salmaan Keshavjee, associate professor of global health and social medicine, authored this blog post about tuberculosis. 

March 19, 2015

More than 200 infectious disease researchers from the Boston area converged at the Broad Institute of MIT and Harvard last week to swap business cards and drug discovery ideas and talk about the biggest medical challenges ahead. Michael Gilmore, Sir William Osler Professor of Ophthalmology at Massachusetts Eye and Ear, is quoted.

March 19, 2015

In a study published online this week, UC San Dieago researchers report that an introduced mutation disabled both normal copies of a pigmentation gene on the fruit fly chromosomes, transmitting itself to the next generation with 97% efficiency—a near-complete invasion of the genome. The secret of its success: an increasingly popular gene-editing toolkit called CRISPR, which the researchers adapted to give the mutation an overwhelming advantage. George Church, Robert Winthrop Professor of Genetics, is quoted.

March 19, 2015

American health care is obsessed with more. But the industry is beginning to realize that more isn’t always what’s best for patients. Atul Gawande, Samuel O. Thier Professor of Surgery at Brigham and Women's Hospital, is mentioned. 

March 19, 2015

A tablet device that can withstand being doused in chlorine has been developed to help medics caring for patients with Ebola. Eric Perakslis, executive director of the Center for Biomedical Informatics at Countway Library, is quoted. This work supported by HMS Center for Biomedical Informatics and the department of global health and social medicine. 

March 19, 2015

Dhruv Khullar, clinical fellow in medicine at Massachusetts General Hospital, authored this article about the efficiency-empathy trade-offs that are an inevitable and inherent tension in medicine.

March 18, 2015

Executives at drug company Actavis knew they had to move fast to avoid a plunge in sales of their top-selling drug, Namenda, a treatment for Alzheimer’s disease that would lose patent protection in July. When that happened, generic knockoffs would flood the market, and doctors and pharmacists could switch patients to the lower-cost equivalents. Jerry Avorn, professor of medicine at Brigham and Women's Hospital, is quoted. 


Submit Photo Requests to HMS
To request photos from the HMS Office of Communications and External Relations, click here.


Tell us about your awards
Share news of your achievements with the larger HMS community,  click here.


Book Reviews
If you are a faculty member who has published a book recently, click here.